ARTham’s clinical program: ART-648, oral selective PDE4 inhibitor, for pemphigoid was awarded three-year R&D grant from the Japan Agency for Medical Research and Development (AMED) Program for Orphan Drugs prior to Designation”.

https://www.amed.go.jp/en/program/list/06/03/001_03-01.html

Pemphigoid, one of the rare diseases in elderly population, is an autoimmune skin disease that causes edematous erythema, itchy blisters, and erosions of the skin and mucous membranes throughout the body. ART-648 is providing therapeutic benefits through inhibiting inflammatory responses in multiple immune and inflammatory cells. With the support from AMED, we will strive to deliver medicines that matter for patients.